Benjamin N. Cardozo School of Law, J.D
Virginia Tech, M.S.
B.S. Biology, Minors: Chemistry, Philosophy
William R. Schmidt, II
Mr. Schmidt’s is a registered patent attorney. His practice includes preparing and prosecuting domestic and international patent applications, counseling clients on intellectual property strategies, and managing patent portfolios in the biotechnology and chemical arts. He has experience prosecuting complex biotechnology and chemical patent applications before the USPTO. Mr. Schmidt has prosecuted numerous patent applications involving nanotechnology and immunotherapy including antibody therapeutics, stem cells, gene therapy, RNAi, vaccines, and targeted drug delivery systems. Mr. Schmidt has extensive experience in numerous areas of U.S. Patent & Trademark Office practice including appeals, application revival, in-person examiner interviews, patent term adjustment, patent term extension, and restriction practice. He also has experience preparing invalidity and non-infringement opinions.
Mr. Schmidt received a Dean’s Merit Scholarship- Top 20%- Cardozo Journal of International
and Comparative Law. Mr. Schmidt obtained a Master’s of Science while performing basic research on microtubule motor protein function. Mr. Schmidt was also a co-author on scientific publications about modulating T-cell signaling for immunotherapy while working as a Research Specialist at the University of Pennsylvania School of Medicine. After University, Mr. Schmidt spent time teaching English in Japan.
Prior to joining Hahn & Associates, Mr. Schmidt was a patent prosecution attorney at a mid-sized patent prosecution boutique for a number of years.
Elhalel MD et al., “CTLA-4-FasL induces alloantigen-specific hyporesponsiveness,” J
Immunol, June 2003, Vol. 170, No. 12, pp. 5842-50.
Dranitzki-Elhalel M et al., “CTLA-4-FasL inhibits allogeneic responses in vivo,” Cell
Immunol, Feb. 2006, Vol. 239, No. 2, pp. 129-35.